Explore

Trendline Trendline
ABS Approves Nuclear Reactor Integration in Vessel Design, Paving Way for Maritime Innovation

ABS Approves Nuclear Reactor Integration in Vessel Design, Paving Way for Maritime Innovation

ABS Approves Nuclear Reactor Integration in Vessel Design, Paving Way for Maritime Innovation
Trendline Trendline
ABS Approves Nuclear Reactor Integration in Cargo Vessel Design, Paving Way for Maritime Innovation

ABS Approves Nuclear Reactor Integration in Cargo Vessel Design, Paving Way for Maritime Innovation

ABS Approves Nuclear Reactor Integration in Cargo Vessel Design, Paving Way for Maritime Innovation
Trendline Trendline
ABS Approves Nuclear Reactor Integration in Vessel Design for Maritime Innovation

ABS Approves Nuclear Reactor Integration in Vessel Design for Maritime Innovation

ABS Approves Nuclear Reactor Integration in Vessel Design for Maritime Innovation
Trendline Trendline
BW Epic Kosan Expands Use of GIT Coatings for Enhanced Fuel Efficiency

BW Epic Kosan Expands Use of GIT Coatings for Enhanced Fuel Efficiency

BW Epic Kosan Expands Use of GIT Coatings for Enhanced Fuel Efficiency
Trendline Trendline
K Line Orders New Car Carriers to Expand European Short Sea Shipping

K Line Orders New Car Carriers to Expand European Short Sea Shipping

K Line Orders New Car Carriers to Expand European Short Sea Shipping
Rapid Read Rapid Read
Department of Energy Marks Milestone with Advanced Reactor Criticality at Idaho National Laboratory

Department of Energy Marks Milestone with Advanced Reactor Criticality at Idaho National Laboratory

The U.S. Department of Energy (DOE) has announced a significant achievement in the field of nuclear energy with the successful completion of a zero-power fueled criticality demonstration of Antares Nuclear's advanced reactor design, the Mark-0, at the Idaho National Laboratory. This marks the first time in over four decades that a new privately developed non-light-water reactor has reached criticality in the United States. The test confirms the reactor's ability to operate safely and sets the stage for future reactors to produce electricity by 2027. This development is part of the DOE's Reactor Pilot Program, which aims to expedite the certification and construction of advanced reactor designs. The program has been bolstered by President Trump's executive order, which set a deadline for these reactors to achieve criticality by July 4th.
Trendline Trendline
First U.S. Test of Modular Nuclear Reactor Achieves Criticality

First U.S. Test of Modular Nuclear Reactor Achieves Criticality

First U.S. Test of Modular Nuclear Reactor Achieves Criticality
Trendline Trendline
Antares' Modular Nuclear Reactor Achieves Criticality at Idaho National Laboratory

Antares' Modular Nuclear Reactor Achieves Criticality at Idaho National Laboratory

Antares' Modular Nuclear Reactor Achieves Criticality at Idaho National Laboratory
Trendline Trendline
BWXT Achieves Milestone with TRISO Fuel in DOE Nuclear Reactor Program

BWXT Achieves Milestone with TRISO Fuel in DOE Nuclear Reactor Program

BWXT Achieves Milestone with TRISO Fuel in DOE Nuclear Reactor Program
Rapid Read Rapid Read
MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

MIT Study Explores Enhanced Mucosal Immunity for Injectable Polio Vaccines

Researchers at the Massachusetts Institute of Technology (MIT) have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The study, published in Science Advances, suggests that the adjuvant, known as Am80, can be delivered using lipid nanoparticles to stimulate immune cells to target the mucosal lining of the intestine. This approach aims to combine the safety of the injectable polio vaccine with the mucosal immunity typically provided by the oral polio vaccine, which some countries have stopped using due to a small risk of infection.
Rapid Read Rapid Read
MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

MIT-Led Study Develops Adjuvant to Enhance Mucosal Immunity in Polio Vaccines

Researchers at the Massachusetts Institute of Technology have developed an experimental adjuvant that could enhance mucosal immunity when used with injectable polio vaccines. The adjuvant, Am80, is delivered using lipid nanoparticles, allowing for a slow release that stimulates immune cells to target the mucosal lining of the intestine. This approach aims to provide the benefits of the oral polio vaccine, which induces mucosal immunity, without its associated risks. Initial tests in rats have shown promising results, with increased production of antibodies necessary for mucosal immunity.
Rapid Read Rapid Read
MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

MIT Researchers Develop Adjuvant to Enhance Injectable Polio Vaccine's Mucosal Immunity

Researchers at the Massachusetts Institute of Technology have developed a new adjuvant that could enhance the mucosal immunity of the injectable polio vaccine. The injectable form of the polio vaccine is effective at preventing illness but does not block virus transmission as effectively as the oral version. The oral vaccine induces a mucosal immune response in the gastrointestinal tract, which is the primary site of virus exposure. However, due to a small risk of infection, several countries have stopped using the oral vaccine. The new adjuvant, known as Am80, is delivered with a lipid nanoparticle that releases it slowly, allowing for a sustained immune response. This approach aims to combine the safety of the injectable vaccine with the mucosal immunity benefits of the oral vaccine, potentially aiding in polio eradication efforts.